• Francois-Xavier Ageron, Angele Gayet-Ageron, Katharine Ker, Timothy J Coats, Haleema Shakur-Still, Ian Roberts, and Antifibrinolytics Trials Collaboration.
• Clinical Trials Unit, London School of Hygiene and Tropical Medicine, London, UK; Emergency Department, Lausanne University Hospital, CHUV, Lausanne, Switzerland. Electronic address: fxageron@gmail.com.
• Br J Anaesth. 2020 Jun 1; 124 (6): 676-683.

BackgroundEarly administration of the antifibrinolytic drug tranexamic acid reduces death from bleeding in trauma and postpartum haemorrhage. We examined how the effectiveness and safety of antifibrinolytic drugs varies by the baseline risk of death as a result of bleeding.MethodsWe performed an individual patient-level data meta-analysis of randomised trials including more than 1000 patients that assessed antifibrinolytics in acute severe bleeding. We identified trials performed between January 1, 1946 and July 5, 2018 (PROSPERO, number 42016052155).ResultsTwo randomised trials were selected where 28 333 patients received tranexamic acid treatment within 3 h after the onset of acute bleeding. Baseline characteristics to estimate the risk of death as a result of bleeding were divided into four categories: Low (0-5%), intermediate (6-10%), high (11-20%), and very high (>20%). Most patients had a low baseline risk of death as a result of bleeding (23 008 [81%]). Deaths as a result of bleeding occurred in all baseline risk categories with 240 (1%), 202 (8%), 232 (14%), and 357 (30%) deaths in the low-, intermediate-, high-, and very high-risk categories, respectively. The effectiveness of tranexamic acid did not vary by baseline risk when given within 3 h after bleeding onset (P=0.51 for interaction term). There was no increased risk of vascular occlusive events with tranexamic acid and it did not vary by baseline risk categories (P=0.25).ConclusionsTranexamic acid appears to be safe and effective regardless of baseline risk of death. Because many deaths are in patients at low and intermediate risk, tranexamic acid use should not be restricted to the most severely injured or bleeding patients.Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.

20 keywords...

hide…